balertatug

Home
Ligands
balertatug

GtoPdb Ligand ID: 13800

Comment: Balertatug is the INN for an anti-CD70 monoclonal antibody. Peptide sequence matches this to claims in patent US8067546B2; Humanized anti-CD70 binding agents and uses thereof [1]. May align with SeaGen's clinical candidate SGN-70/SEA-CD70 that was developed for antitumour activity against CD70-positive cancers (principally myelodysplastic syndrome and acute myeloid leukemia) [2]. The antibody blocks activation of the CD70/CD27 signalling pathway that promotes stemness and proliferation of leukemic blasts. It is engineered to enhance effector functions; antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). Internal company identifier was switched to PF-08046040 when Pfizer acquired SeaGen.

References
1. McDonagh C, Carter P, McEarchern J, Law CL. (2011) Humanized anti-CD70 binding agents and uses thereof. Patent number: US8067546B2. Assignee: Seattle Genetics Inc. Priority date: 19/04/2006. Publication date: 29/11/2011.
2. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ et al.. (2008) Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res, 14 (23): 7763-72. [PMID:19047103]

References

1. McDonagh C, Carter P, McEarchern J, Law CL. (2011)
Humanized anti-CD70 binding agents and uses thereof.
Patent number: US8067546B2. Assignee: Seattle Genetics Inc. Priority date: 19/04/2006. Publication date: 29/11/2011.

2. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ et al.. (2008)
Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
Clin Cancer Res, 14 (23): 7763-72. [PMID:19047103]